Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

L.A. McKeown

September 22, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Daily News

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

Todd Neale

November 27, 2024

News Features

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

Todd Neale

November 13, 2024

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

News Daily News

‘Provocative’ Projections See Semaglutide Slashing CV Events in Adults With ASCVD

Todd Neale

June 27, 2024

News Daily News

Dramatic LDL Drops Seen in PAD Patients With Team-Based Care

L.A. McKeown

June 18, 2024

News Daily News

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Michael O'Riordan

June 14, 2023

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

News Daily News

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Yael L. Maxwell

August 27, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Daily News

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Yael L. Maxwell

January 24, 2018

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

Advertisement

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

GDMT Uptake Remains Dismal in HFrEF: What’s the Right Fix?

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

‘Provocative’ Projections See Semaglutide Slashing CV Events in Adults With ASCVD

Dramatic LDL Drops Seen in PAD Patients With Team-Based Care

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content